{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T22:52:36Z","timestamp":1777330356875,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.clinthera.2009.11.024","type":"journal-article","created":{"date-parts":[[2010,1,26]],"date-time":"2010-01-26T09:59:17Z","timestamp":1264499957000},"page":"2489-2502","source":"Crossref","is-referenced-by-count":70,"title":["Silodosin: A selective \u03b11A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia"],"prefix":"10.1016","volume":"31","author":[{"given":"Sara","family":"Schilit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenza E.","family":"Benzeroual","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.11.024_bib1","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/01.ju.0000078083.38675.79","article-title":"AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations","volume":"170","year":"2003","journal-title":"J Urol."},{"key":"10.1016\/j.clinthera.2009.11.024_bib2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.rcl.2006.07.005","article-title":"Benign prostatic hyperplasia: A review and ultrasound classification","volume":"44","author":"Wasserman","year":"2006","journal-title":"Radiol Clin North Am."},{"key":"10.1016\/j.clinthera.2009.11.024_bib3","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(03)13073-5","article-title":"Benign prostatic hyperplasia [published correction appears in Lancet. 2003;362:496]","volume":"361","author":"Thorpe","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2009.11.024_bib4","series-title":"Campbell-Walsh Urology","article-title":"Benign prostatic hyperplasia: Etiology, pathophysiology, epidemiology, and natural history","author":"Roehrborn","year":"2007"},{"key":"10.1016\/j.clinthera.2009.11.024_bib5","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/j.1742-1241.2008.01785.x","article-title":"Benign prostatic hyperplasia as a progressive disease: A guide to the risk factors and options for medical management","volume":"62","author":"Emberton","year":"2008","journal-title":"Int J Clin Pract."},{"key":"10.1016\/j.clinthera.2009.11.024_bib6","first-page":"333","article-title":"Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: Issues and potential complications","volume":"108","author":"Fine","year":"2008","journal-title":"J Am Osteopath Assoc."},{"key":"10.1016\/j.clinthera.2009.11.024_bib7","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0090-4295(98)00140-X","article-title":"Alpha-blockade therapy for benign prostatic hyperplasia: From a nonselective to a more selective alpha1A-adrenergic antagonist","volume":"51","author":"Beduschi","year":"1998","journal-title":"Urology"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.11.024_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0090-4295(03)00480-1","article-title":"Lower urinary tract symptoms\/benign prostatic hyperplasia: Maintaining symptom control and reducing complications","volume":"62","author":"O\u2019Leary","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2009.11.024_bib9","first-page":"1403","article-title":"Diagnosis and management of benign prostatic hyperplasia","volume":"77","author":"Edwards","year":"2008","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.clinthera.2009.11.024_bib10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1442-2042.2007.01956.x","article-title":"Alpha1-adrenoceptor subtypes and lower urinary tract symptoms","volume":"15","author":"Schwinn","year":"2008","journal-title":"Int J Urol."},{"key":"10.1016\/j.clinthera.2009.11.024_bib11","series-title":"Rapaflo (silodosin) [package insert]","year":"2009"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2009.11.024_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1464-410X.2001.00116.x","article-title":"The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms","volume":"88","author":"Schwinn","year":"2001","journal-title":"BJU Int."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.11.024_bib13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1464-410X.1998.0810s1048.x","article-title":"Current status of research on prostate-selective alpha 1-antagonists","volume":"81","author":"Kawabe","year":"1998","journal-title":"Br J Urol."},{"key":"10.1016\/j.clinthera.2009.11.024_bib14","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.clinthera.2004.11.006","article-title":"Role of the newer alpha1-adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms","volume":"26","author":"Lowe","year":"2004","journal-title":"Clin Ther."},{"key":"10.1016\/j.clinthera.2009.11.024_bib15","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0022-5347(05)67426-5","article-title":"Tissue selectivity of KMD-3213, an alpha(1)-adrenoreceptor antagonist, in human prostate and vasculature","volume":"164","author":"Murata","year":"2000","journal-title":"J Urol."},{"key":"10.1016\/j.clinthera.2009.11.024_bib16","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0026-895X(25)10243-5","article-title":"KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: Characterization using recombinant human alpha 1-adrenoceptors and native tissues","volume":"48","author":"Shibata","year":"1995","journal-title":"Mol Pharmacol."},{"key":"10.1016\/j.clinthera.2009.11.024_bib17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1254\/jjp.90.131","article-title":"Effects of KMD-3213, a uroselective alpha 1A-adrenoceptor antagonist, on the tilt-induced blood pressure response in normotensive rats","volume":"90","author":"Akiyama","year":"2002","journal-title":"Jpn J Pharmacol."},{"key":"10.1016\/j.clinthera.2009.11.024_bib18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-3565(24)35074-8","article-title":"KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model","volume":"291","author":"Akiyama","year":"1999","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.clinthera.2009.11.024_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1046\/j.1442-2042.2001.00277.x","article-title":"Effect of KMD-3213, an alpha1A-adrenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogs","volume":"8","author":"Akiyama","year":"2001","journal-title":"Int J Urol."},{"key":"10.1016\/j.clinthera.2009.11.024_bib20","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/nau.20312","article-title":"Uroselectivity in male dogs of silodosin (KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia","volume":"25","author":"Tatemichi","year":"2006","journal-title":"Neurourol Urodyn."},{"key":"10.1016\/j.clinthera.2009.11.024_bib21","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1464-410X.2006.06448.x","article-title":"Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: Results of a phase III randomized, placebo-controlled, doubleblind study in Japanese men","volume":"98","author":"Kawabe","year":"2006","journal-title":"BJU Int."},{"key":"10.1016\/j.clinthera.2009.11.024_bib22","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1442-2042.2008.02154.x","article-title":"Early efficacy of silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia","volume":"15","author":"Takao","year":"2008","journal-title":"Int J Urol."},{"key":"10.1016\/j.clinthera.2009.11.024_bib23","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1016\/j.juro.2009.02.034","article-title":"Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: Pooled results of 2 phase 3 studies","volume":"181","author":"Marks","year":"2009","journal-title":"J Urol."},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2009.11.024_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1464-410X.2006.06104.x","article-title":"Impact of medical treatments for benign prostatic hyperplasia on sexual function","volume":"97","author":"Giuliano","year":"2006","journal-title":"BJU Int."},{"key":"10.1016\/j.clinthera.2009.11.024_bib25","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1111\/j.1743-6109.2008.00779.x","article-title":"Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective alpha1A-blocker in normal volunteers","volume":"5","author":"Kobayashi","year":"2008","journal-title":"J Sex Med."},{"key":"10.1016\/j.clinthera.2009.11.024_bib26","series-title":"Presented at: Annual Meeting of the New England Section of the American Urological Association","article-title":"Safety of silodosin, a highly uroselective alpha-1 adrenergic receptor antagonist: Combined results from an open-label extension of 2 randomized, placebo-controlled, parallel-group studies","author":"Gittelman","year":"2008"},{"key":"10.1016\/j.clinthera.2009.11.024_bib27","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1345\/aph.1K679","article-title":"Intraoperative floppy iris syndrome associated with alpha1-adrenergic receptor antagonists","volume":"42","author":"Cantrell","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2009.11.024_bib28","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/j.jcrs.2008.08.031","article-title":"ASCRS White Paper: Clinical review of intraoperative floppy-iris syndrome","volume":"34","author":"Chang","year":"2008","journal-title":"J Cataract Refract Surg."},{"key":"10.1016\/j.clinthera.2009.11.024_bib29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/ICU.0b013e32831bc0ad","article-title":"Intraoperative floppy iris syndrome","volume":"20","author":"Abdel-Aziz","year":"2009","journal-title":"Curr Opin Ophthalmol."},{"key":"10.1016\/j.clinthera.2009.11.024_bib30","first-page":"1148","article-title":"Intraoperative floppy iris syndrome associated with tamsulosin","volume":"53","author":"Brogden","year":"2007","journal-title":"Can Fam Physician."},{"key":"10.1016\/j.clinthera.2009.11.024_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/bjo.2006.103036","article-title":"Floppy iris behaviour during cataract surgery: Associations and variations","volume":"91","author":"Chadha","year":"2007","journal-title":"Br J Ophthalmol."},{"key":"10.1016\/j.clinthera.2009.11.024_bib32","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jcrs.2007.03.032","article-title":"Intraoperative floppy-iris syndrome associated with alpha1-adrenoreceptors: Comparison of tamsulosin and alfuzosin","volume":"33","author":"Blouin","year":"2007","journal-title":"J Cataract Refract Surg."},{"key":"10.1016\/j.clinthera.2009.11.024_bib33","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajo.2006.07.046","article-title":"Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha(1)-adrenoceptor antagonist","volume":"143","author":"Oshika","year":"2007","journal-title":"Am J Ophthalmol."},{"key":"10.1016\/j.clinthera.2009.11.024_bib34","series-title":"Red Book: Pharmacy's Fundamental Reference","year":"2009"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809004147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809004147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T23:43:18Z","timestamp":1739749398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809004147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0149291809004147"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.11.024","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}